株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:慢性腎疾患の疫学的予測

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 281804
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
EpiCast Report:慢性腎疾患の疫学的予測 EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2022
出版日: 2013年08月31日 ページ情報: 英文 78 Pages
概要

全世界の成人(30歳以上)人口に対する慢性腎疾患(CKD)有病率は7.2%と推計されています。一般に、女性の方が男性よりも発症率が高く、また南アジア系・アフリカ系の人々の発症率が高くなる傾向があります。南アジア系は糖尿病、アフリカ系は高血圧の有病率の高さに起因するものと思われます。

当レポートでは、世界の主要国における慢性腎臓病(CKD)の発症状況と今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要

第3章 疫学

  • 疾患の概要
  • リスク要因と共存症
    • 腎臓病・慢性腎疾患の併発患者は、他の合併症も併発しやすい
    • 高血圧患者:末期腎不全(ESRD)発症リスクが3倍高い
    • 若年層での肥満患者:後で慢性腎疾患を発症するリスクが非常に高い
    • 女性は男性よりも、慢性腎疾患発症リスクが2倍高い
    • 家族歴:慢性腎疾患のリスクが最大10倍まで高くなる
    • 心血管疾患(CVD):4〜5期の慢性腎疾患患者の約40%が発症している
  • 世界的な傾向
    • 米国
    • 欧州主要5ヶ国
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • 慢性腎疾患の疫学的予測(今後10年間分)
    • 慢性腎疾患の有病者数
    • 年齢層別の有病者数
    • 男女別の有病者数
    • 年齢調整済みの有病者数
    • 病期別の有病者数
  • 議論
    • 結論と疫学的傾向
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER040

Summary

Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. CKD affects people of all ages; however, the risk is higher in people ages 65 years and older. Globally, the estimated prevalence of CKD is 7.2% in adults over the age of 30 years. The disease is more common in women than men, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin. Based on the glomerular filtration rate, the Kidney Disease Outcomes Quality Initiative (KDOQI) classified CKD into five stages in 2002. Each stage of CKD requires different tests and treatments for management of the disease.

This report provides an overview of the risk factors and the global and historical trends for CKD in the 6MM. In addition, the report includes a 10-year epidemiological forecast (2012-2022) of the prevalent cases of CKD segmented by sex, age (in five-year increments beginning at age 20 and ending at age =85 years), and stage in these markets.

GlobalData's epidemiological forecast is supported by data from country-specific studies published in peer-reviewed journals. GlobalData epidemiologists obtained age- and sex-specific prevalence data for CKD in the 6MM from nationally-representative studies in each country to forecast the total prevalent cases of CKD during the forecast period (2012-2022).

A major strength of this analysis is the use of country-specific data and a uniform methodology across all the markets to forecast the prevalent cases of CKD. In addition, GlobalData epidemiologists provide segmentation of the CKD prevalent cases by stage per the KDOQI guidelines in each market, despite the stage-specific data being limited to certain age groups and stages.

Scope

  • The Chronic Kidney Disease EpiCast report provides an overview of the risk factors and global trends of chronic kidney disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012-2022) of the prevalent cases of chronic kidney disease segmented by age (in five-year increments beginning at age 20 and ending at age =85 years), sex, and stage (1-5) in the 6MM
  • The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists
  • In-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
  • Quantify patient populations in the global chronic kidney disease market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for V therapeutics in each of the markets covered.
  • Identify the percentage of chronic kidney disease prevalent cases that are in stages 1, 2, 3, 4, and 5.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Epidemiology

  • 3.1. Disease Overview
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Diabetic CKD patients are more likely to have complications of CKD
    • 3.2.2. Hypertensive patients are three times more likely to develop ESRD
    • 3.2.3. Obesity at a younger age significantly increases the risk for CKD later in life
    • 3.2.4. Women are twice as likely to develop CKD as men
    • 3.2.5. Family history increases the risk of developing CKD by up to 10 times
    • 3.2.6. CVD is prevalent in almost 40% of CKD patients in stages 4 and 5
  • 3.3. Global Trends
    • 3.3.1. United States
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Sources Not Used
  • 3.5. Epidemiology Forecast for CKD (2012-2022)
    • 3.5.1. Prevalent Cases of CKD
    • 3.5.2. Age-Specific Prevalent Cases of CKD
    • 3.5.3. Sex-Specific Prevalent Cases of CKD
    • 3.5.4. Age-Standardized Prevalence of CKD
    • 3.5.5. Prevalent Cases of CKD by Stage
  • 3.6. Discussion
    • 3.6.1. Conclusions on Epidemiological Trends
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: KDOQI Classification of CKD
  • Table 2: Risk Factors and Comorbidities for CKD
  • Table 3: Trends in the Prevalence (%) of CKD by Stage in the US
  • Table 4: Trends in the Incidence and Prevalence of ESRD in the US (Cases per Million)
  • Table 5: Trends in the Incidence and Prevalence of RRT for ESRD in the US (Cases per Million)
  • Table 6: Trends in the Incidence and Prevalence of RRT for ESRD in Europe (Cases per Million)
  • Table 7: Trends in the Incidence and Prevalence of ESRD in France (Cases per Million)
  • Table 8: Trends in the Incidence and Prevalence of RRT for ESRD in France (Cases per Million)
  • Table 9: Trends in the Incidence and Prevalence of ESRD in Germany (Cases per Million)
  • Table 10: Trends in the Incidence and Prevalence of RRT for ESRD in Germany (Cases per Million)
  • Table 11: Trends in the Incidence and Prevalence of ESRD in Italy (Cases per Million)
  • Table 12: Trends in the Incidence* and Prevalence of RRT for ESRD in Italy (Cases per Million)
  • Table 13: Trends in the Incidence and Prevalence of ESRD in Spain (Cases per Million)
  • Table 14: Trends in the Incidence and Prevalence of RRT for ESRD in Spain (Cases per Million)
  • Table 15: Trends in the Incidence and Prevalence of ESRD in the UK (Cases per Million)
  • Table 16: Trends in the Incidence and Prevalence of RRT for ESRD in the UK (Cases per Million)
  • Table 17: Protocol For CKD Case Ascertainment Across All Studies Used in This Analysis
  • Table 18: 6MM, Sources of CKD Prevalence and Stage Data
  • Table 19: 6MM, Prevalent Cases of CKD, Ages >20 Years, Men and Women, (N=Millions), 2012-2022
  • Table 20: 6MM, Prevalent Cases of CKD, by Age, Men and Women, (N=Millions), (Row %), 2012
  • Table 21: 6MM, Prevalent Cases of CKD, by Sex, Ages ≥20 Years, N (Row %), 2012
  • Table 22: 6MM, Prevalent Cases of CKD by Stage, Ages ≥ 20 Years, Men and Women, N (Row %), 2012

List of Figures

  • Figure 1: Trends in the Prevalence (%) of CKD by Stage in the US
  • Figure 2: Trends in the Incidence and Prevalence of ESRD in the US (Cases per Million)
  • Figure 3: Trends in the Incidence and Prevalence (%) of RRT for ESRD in the US (Cases per Million)
  • Figure 4: Trends in the Incidence and Prevalence of RRT for ESRD in Europe (Cases per Million)
  • Figure 5: Trends in the Incidence and Prevalence of ESRD in France (Cases per Million)
  • Figure 6: Trends in the Incidence and Prevalence of RRT for ESRD in France (Cases per Million)
  • Figure 7: Trends in the Incidence and Prevalence of ESRD in Germany (Cases per Million)
  • Figure 8: Trends in the Incidence and Prevalence of RRT for ESRD in Germany (Cases per Million)
  • Figure 9: Trends in the Incidence and Prevalence of ESRD in Italy (Cases per Million)
  • Figure 10: Trends in the Incidence* and Prevalence of RRT for ESRD in Italy (Cases per Million)
  • Figure 11: Trends in the Incidence and Prevalence of ESRD in Spain (Cases per Million)
  • Figure 12: Trends in Incidence and Prevalence of RRT for ESRD in Spain (Cases per Million)
  • Figure 13: Trends in the Incidence and Prevalence of ESRD in the UK (Cases per Million)
  • Figure 14: Trends in the Incidence and Prevalence of RRT for ESRD in the UK (Cases per Million)
  • Figure 15: 6MM, Prevalent Cases of CKD, Ages >20 Years, Men and Women, 2012-2022
  • Figure 16: 6MM, Prevalent Cases of CKD, by Age, Men and Women, 2012
  • Figure 17: 6MM, Prevalent Cases of CKD, by Sex, Ages≥ 20 Years, 2012
  • Figure 18: 6MM, Age-Standardized Prevalence of CKD (%), Ages ≥20 Years, Men and Women, 2012
  • Figure 19: 6MM, Prevalent Cases of CKD by Stage, Ages ≥20 Years, Men and Women, 2012
Back to Top